Press Release Headlines

MERS and Ebola Replikins Synthetic Vaccine-Blocker™ Candidates Presented at Meeting of Int’l Society for Neglected Tropical Diseases at Wellcome Trust May 20th

Predictions Based on Over 3 Million Automated Quantitative Gene Sequence Analyses

Freeze-dried Vaccine-Blocker Candidates Now Available for Challenge Testing

LONDON, June 4, 2015 /PRNewswire/ — Replikins Ltd. presented MERS and Ebola Synthetic Vaccine-Blocker candidates at a meeting of the International Society for Neglected Tropical Diseases (ISNTD). At the meeting, held at the Wellcome Trust, London on May 20, 2015, over 3 million automated quantitative gene sequence analyses of Mers and Ebola and controls were reported by Dr. Samuel Bogoch. Replikins surveillance predictive analyses of all MERS-CoV, Ebola, and control virus specimens published in Pubmed from 1976 to May 2015 led to the correct prediction one to two years in advance of major outbreaks and cessations of the Mers and Ebola viruses including those of 2014-2015.

Logo –

Further, the Replikin sequences identified in the quantitative genomic analyses are the basis of two new Replikins Synthetic Vaccine-Blockers™ for Mers and Ebola. The Mers and Ebola synthetic vaccines, produced in 7 days, elicited statistically significant antibody immune responses in both mice and rabbits.

These freeze-dried Synthetic Vaccine-Blockers are now available for challenge testing.

Contact: Samuel Bogoch, Email, 646-320-5910